Adult Paget's disease of bone: a review

被引:48
|
作者
Tuck, Stephen Paul [1 ,2 ]
Layfield, Robert [3 ]
Walker, Julie [4 ]
Mekkayil, Babitha [2 ]
Francis, Roger [1 ]
机构
[1] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England
[2] James Cook Univ Hosp, Rheumatol, Middlesbrough, Cleveland, England
[3] Univ Nottingham, Sch Med, Sch Life Sci, Dept Biochem, Nottingham, England
[4] James Cook Univ Hosp, Dept Histopathol, Middlesbrough, Cleveland, England
关键词
Paget's disease of bone; pathogenesis; management; complications; ZOLEDRONIC ACID; HEARING-LOSS; BIOCHEMICAL MARKERS; TURNOVER MARKERS; SINGLE INFUSION; RISEDRONATE; PATHOGENESIS; PAMIDRONATE; MANAGEMENT; MUTATIONS;
D O I
10.1093/rheumatology/kew430
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Adult PD of bone is the second commonest metabolic bone condition after osteoporosis. The condition is characterized by increased bone cell activity, with bone-resorbing osteoclasts often larger and containing more nuclei than normal, and osteoblasts producing increased amounts of disorganized bone. This leads to expanded bone of poor quality possessing both sclerotic and lytic areas. PD of bone has a strong genetic element, with a family history being noted in 10-20% of cases. A number of genetic defects have been found to be associated with the condition. The most common disease-associated variants identified affect the SQSTM1 gene, providing insights into disease aetiology, with the clinical value of knowledge of SQSTM1 mutation status currently under active investigation. The diagnosis may be suggested by an isolated raised total ALP without other identifiable causes. This can be confirmed on plain X-rays and the extent determined by isotope bone scan. The mainstays of treatment are the bisphosphonates, especially i.v. zoledronate, which results in long-term suppression of bone turnover. ALP is the usual means of monitoring the condition, although more specific bone turnover markers can be helpful, especially in coincident liver disease. Patients should be followed up to monitor for biochemical relapse or development of complications, which may require medical or surgical intervention.
引用
收藏
页码:2050 / 2059
页数:10
相关论文
共 50 条
  • [21] Paget's disease of bone
    Appelman-Dijkstra, Natasha M.
    Papapoulos, Socrates E.
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 32 (05) : 657 - 668
  • [22] Paget's disease of bone
    Thomas, P
    Howarth, D
    NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (03): : 160 - 160
  • [23] Paget's disease of bone
    Cundy, Tim
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2018, 80 : 5 - 14
  • [24] Paget's disease of bone
    Ooi, CG
    Fraser, WD
    POSTGRADUATE MEDICAL JOURNAL, 1997, 73 (856) : 69 - 74
  • [25] Paget's disease of bone
    Walsh, JP
    MEDICAL JOURNAL OF AUSTRALIA, 2004, 181 (05) : 262 - 265
  • [26] Paget's disease of bone
    Whyte, Michael P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (06): : 593 - 600
  • [27] Paget's disease of bone
    Holgado Perez, Susana
    Salles Lizarzaburu, Meritxell
    Olive Marques, Alejandro
    MEDICINA CLINICA, 2008, 131 (13): : 509 - 512
  • [28] Paget's Disease of Bone
    Gennari, Luigi
    Rendina, Domenico
    Falchetti, Alberto
    Merlotti, Daniela
    CALCIFIED TISSUE INTERNATIONAL, 2019, 104 (05) : 483 - 500
  • [29] Paget's Disease of Bone
    Balani, Ankit
    Marda, Sapna S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (13): : 1264 - 1264
  • [30] Paget's disease of bone
    Tran, HA
    MEDICAL JOURNAL OF AUSTRALIA, 2005, 182 (03) : 138 - 139